Midday Report: Frequency (FREQ) Shares Climb for August 5

Equities Staff  |

Frequency Therapeutics Inc (NASDAQ: FREQ) has risen $0.14 (6.70%) and sits at $2.23, as of 11:52:10 est on August 5.

129,274 shares have been traded today.

The Company rose 10.29% over the last 5 days and shares advanced 47.06% over the last 30 days.

Frequency anticipates its next earnings on 2022-08-11.

For technical charts, analysis, and more on Frequency visit the company profile.

About Frequency Therapeutics Inc

Frequency Therapeutics is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The Company's progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. The Company's lead product candidate, FX-322, is designed to regenerate auditory hair cells to restore hearing function. FX-322 is being evaluated in multiple ongoing clinical studies in patients with sensorineural hearing loss. The Company also is evaluating additional diseases where its PCA approach could create functional tissue, including in a pre-clinical program in multiple sclerosis.

To get more information on Frequency Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: Frequency Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content